



Dia-League

A Workshop on New Frontiers in Diabetes

28 FEB 2016 – AGRA, UTTAR PRADESH

Dia-League

"Dia League was held at The Gateway, Fatehabad Road Agra, Taj Ganj, Agra – 282 001, Uttar Pradesh. It was planned and organized by of Asian Society of Continuing Medical Education.

The sole objective of the CME was to update the practicing doctors about Diabetes mellitus, level of morbidity and mortality due to diabetes and its associated spectrum of complications and diabetes management as the disease is now highly visible across all societies within India.

The session was open with an introductory session by Asian Society of continuing Medical Education and followed by the scientific agenda.

Date : 28th Feb 2016.
Venue : The Gateway, Fatehabad Road, Agra, Uttar Pradesh
Total Participants : 45

TOPICS :

- 1. DPP-4 Inhibitors: Have we optimized their role in the treatment of patients with Type 2 Diabetes**
- 2. Placement of Sulphonylurea in the present scenario?**
- 3. Case study – T2DM with recurrent hypoglycaemia**
- 4. The role of combination therapies in early, Intensive management of newly diagnosed Type 2 Diabetes with marked glycaemia**
- 5. The act of balancing between the newer treatment options in T2DM**
 - Yes to DPPIV Inhibitors
 - Yes to SGLT2 Inhibitors
- 6. Cross Talk : Managing Diabetic patient with CV comorbid conditions**
 - Cardiologist perspective
 - Diabetologist perspective
 - AGP Workshop

Dia-League

MODERATOR, CHAIRPERSONS AND FACULTIES



Dr. (Prof.) Daya Kishore Hazra
MBBS, M.D.

**Director-International Society
of Radiolabeled Blood Elements**



Dr. Nitin Ranjan Gupta
MBBS, M.D.

**Consultant Diabetologist and
Endocrinologist**



Dr. Navnit Agarwal
MBBS MD FCCP

**(Ret.) Prof. & Head of Dept.
(Dept. of Medicine)
MLB Medical College Jhansi**



Dr. C.P. Singh
MBBS MD (Medicine)

**Consultant Physician and
Diabetologist, Jigyasa Medical
Centre, Moradabad**



Dr. Manoj Kumar Srivastava
MBBS MD (Med)

**Consultant Physician and
Diabetologist, Manasvi
Diabetes clinic, Lucknow**



Dr. Sunil Bansal
MD, FIACM

**Chairman Bansal Hospital and
Bansal Diabetes Centre, Agra**



Dr. Anubhav Thukral
MBBS, MD, DM

**Consultant Endocrinologist at
Nova superspeciality hospitals,
Chunniganj**



Dr. Amit Kumar Das
MBBS, MD

**Specialist (Medicine),
Composite Hospital, CRPF,
Muzaffarpur**



Dr. Navneet Agarwal
MBBS, MD

**Consultant Physician &
Diabetologist at Diabetes,
Obesity & Thyroid Centre,
Gwalior**



Dr. Sandeep Kharb
MBBS, MD, DNB (Endo.)

**Consultant Endocrinologist at
ASIAN hospital, Faridabad
and Paras hospital, Gurgaon**



Dr. Atul Kulshreshtha
MBBS MD

**Consultant Diabetologist at
Agra.**

Dr. Y P Munjal
MBBS, MD (Med)

**Consultant Endocrinologist at
ASIAN hospital, Faridabad
and Paras hospital, Gurgaon**

1. Dr. Navneet Agarwal discussed about **DPP-4 Inhibitors: Have we optimized their role in the treatment of patients with Type 2 Diabetes.** The scientific session was deliberated on:

- What are incretins?
- Gastric Inhibitory Polypeptide (GIP)
- GLP-1 Effects in Humans
- Dipeptidyl Peptidase-IV Antagonists , Its Safety and Efficacy
- Glimepiride vs Vildagliptin – Asian study
- Cardiovascular Safety
- Most common side effects
- Weight and DPP4 inhibitors
- Gliptin: no weight gain
- Cardiovascular Effects
- Glycemic Variability
- DPP-IV Inhibitors and CV Events
- Merits over SGLT2 Inhibitors
-

2. Dr. M. K. Srivastava talked about **Placement of Sulphonylurea in the present scenario?** The informative session was highlighted upon: -

- Insulin Secretion (Glimepiride)
- Therapeutic actions
- Attributes of sulphonylureas
- Type 2 Diabetes is a Dual Problem
- Unique Dual Mode of Action
- Acting on Both Phases of Insulin Secretion
- Glimepiride Controls Glycemia with Less Insulin Secretion
- Glimepiride : Efficacy Proven in Monotherapy
- Efficacy: Glimepiride + Gliptin Combination
- Safety: Hypoglycemia vs Glibenclamide
- University Group Diabetes Program
- Cardiovascular Safety: Ischemic Preconditioning
- Research Design and methods
- Advantages of Metformin + Sulphonylurea Combination
- SU role in management
- Special situation

3. Dr. Sunil Bansal discussed about **Case study – T2DM with recurrent hypoglycaemia.** The scientific session was based on: -

- Case History - Known T2D with hypoglycemia
- What should be the next course of action?
- The Benefits vs. Risks of Diabetes Therapy Must be Assessed for Each Patient
- The risk of hypoglycaemia during oral anti-diabetic agents is substantially associated with the use of sulphonylureas
- Hypoglycaemia-Clinical Impact

Dia-League

- Hypoglycaemia and cardiovascular events in ADVANCE
- The possible consequences of hypoglycaemia
- Even Silent Hypoglycemia Induces Cardiac Arrhythmias Diabetes 2014
- What is the solution in type 2 diabetes treatment?
- AGI as 2nd line therapy
- Thiazolidenidiones (TZDs) as 2nd line therapy
- Gliptins (DPP4i) as 2nd line therapy
- SGLT2 inhibitors as 2nd line therapy
- NICE guideline on DPP-4 Inhibitors

4. Dr. VN Kausal discussed about **The role of combination therapies in early, Intensive management of newly diagnosed Type 2 Diabetes with marked glycaemia**. The scientific talk was deliberated on: -


- Diabetes Remission After Intensive Insulin Therapy in New Onset T2DM
- Insulin and its Barriers
- Early combination therapy for the treatment of type 2 DM: Systematic Review and Meta analysis
- Initial Management of severe Hyperglycemia in patients with Type 2 Diabetes: An Observational Study
- The ideal components for combination therapy?
- Drawbacks of the stepwise approach
- Potential advantages of early combination therapy
- Choosing oral antidiabetic agents: mechanism of action
- Combination therapy for type 2 diabetes

5. Dr. Anubhav Thukral talked about **YES to DPP4 Inhibitors**. The scientific session highlighted following: -

- Gliptin Vs Gliflozins
- Gliptin Vs Gliflozins
- Evolutionary Decline in incidence of hypoglycemia and weight gain
- The incretin effect is diminished in patients with type 2 diabetes
- DPP4 Inhibitors and Basal Insulin
- Metformin Synergism
- What is happening at pancreatic level? Normal person
- Concept of pancreatic offloading? SGLT2 Inhibitors On Diabetes
- Concept of tissue offloading?
- Genital Mycotic Infections
- SGLT2 in Autonomic neuropathy
- How to individualize?

6. Dr. YP Munjal talked about Ambulatory Glucose Profile (AGP). His scientific session was based on: -

- Flash Glucose Monitoring
- The FreeStyle Libre Pro system
- FreeStyle Libre Pro sensor features
- Measuring glucose levels in interstitial fluid (ISF)
- FreeStyle Libre Pro software features
- Conventional CGM Traces
- Rationale for Ambulatory Glucose Profile (AGP)
- The AGP 14-day Profile
- Interpreting the AGP Graph



Dia-League

SNAPSHOTS

